Naumann Chaudry

Naumann Chaudry has an extensive work experience in the pharmaceutical industry. Naumann is currently serving as the Vice President and Head of US Regulatory Affairs at MorphoSys since March 2023. Prior to that, they worked at Takeda as the VP of Global Regulatory Affairs and US Regulatory Affairs from March 2022 to 2023. Before joining Takeda, Naumann was associated with Gilead Sciences for a significant period. At Gilead Sciences, they held several roles including Executive Director of Global Regulatory Affairs Strategy for Inflammation, Executive Director of Regulatory Affairs advertising and promotion in addition to being the Head for Canada. Naumann worked at Novartis as the Director of Drug Regulatory Affairs from June 2010 to December 2011. Prior to that, Naumann was associated with Pfizer Pharmaceuticals in various roles such as Director of Worldwide Regulatory Strategy, Associate Director of Worldwide Regulatory Strategy, Senior Manager of Worldwide Regulatory Strategy. Naumann also served as Clinical Study Manager and Senior Associate Clinical Study Manager during their tenure at Pfizer. Naumann's career in the pharmaceutical industry began at PPD where they worked as a Clinical Research Fellow from July 2000 to June 2001.

Naumann Chaudry began their education journey in 1993 at Rutgers University, where they pursued a Bachelor of Science (BS) degree in Pharmacy. Naumann successfully completed this program in 1999.

Following their undergraduate studies, they continued their academic pursuits at the University of North Carolina at Chapel Hill. From 1999 to 2001, Chaudry engaged in a Clinical Research Fellowship, specializing in Clinical Research and Drug Development.

Returning to Rutgers University, Chaudry once again enrolled in their Pharmacy program. Naumann completed their studies and obtained a PharmD degree from Rutgers in 1999.

Based on the provided information, it can be inferred that Naumann Chaudry has focused their education on Pharmacy, with additional specialization in Clinical Research and Drug Development.